Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Familial Amyloid Polyneuropathy Industry Expected To Reach By 2029, Starting From 2025 Levels?
The familial amyloid polyneuropathy market has experienced substantial expansion in recent times. Projections indicate its value will rise from $1.52 billion in 2024 to $1.65 billion by 2025, at a compound annual growth rate (CAGR) of 8.4%. This historical growth is linked to factors such as the increasing occurrence of familial amyloid polyneuropathy, elevated awareness and diagnosis rates driven by advancements in genetic testing, the wider acceptance of new therapeutic choices and targeted interventions, expanded investment in research and development for amyloidosis treatments, and an expanding elderly population vulnerable to amyloid-related neuropathies.
The market size for familial amyloid polyneuropathy is anticipated to experience substantial expansion in the coming years. It is projected to reach $2.25 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.1%. The expansion during the forecast period can be attributed to increasing government initiatives and funding supporting treatments for rare diseases, a growing number of clinical trials evaluating innovative therapeutic candidates, rising patient advocacy and support groups driving demand for improved therapies, enhanced accessibility to healthcare infrastructure in emerging markets, and the increasing availability of advanced diagnostic tools. Significant trends expected in the forecast period include advancements in genetic sequencing technologies, the integration of personalized medicine, technological improvements in biomarker identification, progress in drug delivery systems, and the incorporation of digital health tools and telemedicine.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24532&type=smp
Which Drivers Are Impacting The Familial Amyloid Polyneuropathy Market?
The increasing attention on gene therapy is anticipated to boost the expansion of the familial amyloid polyneuropathy market in the future. This therapeutic approach involves altering or substituting faulty genes to tackle the root causes of illnesses. It is gaining traction because it targets and corrects genetic defects, providing durable or permanent cures instead of merely alleviating symptoms. Specifically for familial amyloid polyneuropathy, gene therapy aims to rectify or silence the flawed transthyretin (TTR) gene, thereby preventing the creation of detrimental amyloid protein. This action aids in reducing amyloid deposits, which in turn slows the disease’s advancement and maintains nerve function. For example, data from July 2023, shared by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that at the close of the first quarter of 2023, 247 gene therapies were in Phase II. This figure subsequently increased by 5% to 260 by the conclusion of the second quarter. Consequently, the increased emphasis on gene therapy is stimulating the growth of the familial amyloid polyneuropathy market.
What Are The Leading Segments Analyzed In The Familial Amyloid Polyneuropathy Market?
The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
Which Competitive Trends Are Defining The Familial Amyloid Polyneuropathy Market Structure?
Leading companies active in the familial amyloid polyneuropathy market are focusing on developing advanced treatment solutions, such as RNA interference (RNAi) therapeutics, aiming to slow disease progression and enhance patient outcomes. RNA interference (RNAi) therapeutics are sophisticated treatments that silence genes responsible for disease by targeting their messenger RNA (mRNA). This approach obstructs the creation of harmful proteins, tackling genetic diseases at their origin. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, introduced AMVUTTRA (vutrisiran), which secured approval from the Food and Drug Administration (FDA) for the treatment of cardiomyopathy resulting from wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is administered as four subcutaneous doses annually and is designed to treat both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). By decreasing the production of transthyretin (TTR) protein, the fundamental cause of the disease, it notably reduces cardiovascular mortality, hospitalizations, and urgent heart failure visits, as shown in the HELIOS-B Phase 3 clinical trial.
Which Global Market Leaders Are Shaping The Future Of The Familial Amyloid Polyneuropathy Sector?
Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, YolTech Therapeutics.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Familial Amyloid Polyneuropathy Industry?
North America was the largest region in the familial amyloid polyneuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Familial Amyloid Polyneuropathy Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24532&type=smp
Browse Through More Reports Similar to the Global Familial Amyloid Polyneuropathy Market 2025, By The Business Research Company
Peripheral Neuropathy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Transthyretin Amyloidosis Treatment Global Market Report 2025
Diabetic Neuropathy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model